<DOC>
	<DOCNO>NCT02691052</DOCNO>
	<brief_summary>Current study result superiority combination nab-paclitaxel gemcitabine vs. gemcitabine mono therapy , data available yet quality life ( QoL ) combination therapy . In framework German multicenter prospective , observational study ( 'QoliXane ' ) , detailed QoL-data collect . QoL development treatment analyze data compare exist data gemcitabine mono therapy . QoL course therapy collect use EORTC C30 questionnaires month 6-month period . Additionally patient request answer supplementary questionnaire address e.g . fear related QoL deterioration side effect chemotherapy . Primary endpoint proportion patient maintain Global Health Status/QoL 3 month ( 10 point threshold ) . 600 patient shall enrol 90 study site Germany .</brief_summary>
	<brief_title>Observational Study Quality Life Patients Receiving Nab-paclitaxel/Gemcitabine First Line Therapy , Including Translational Program</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>metastatic pancreatic carcinoma previous therapy metastatic stage plan firstline therapy nabpaclitaxel gemcitabine previous therapy metastatic stage patient unable understand study give inform consent patient unable answer quality life questionnaire</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>metastatic</keyword>
</DOC>